MEI Pharma, Inc. (NASDAQ:MEIP) Files An 8-K Other EventsItem 8.01. Other Events.
On June4, 2018, MEI Pharma, Inc. issued two press releases relating to the presentation of clinical data at the 2018 America Society of Clinical Oncology (ASCO) Annual Meeting. A copy of the press release relating to Phase 1b clinical data for ME-401 in patients with indolent B-Cell Malignancies is attached hereto as Exhibit 99.1 and a copy of the press release relating to clinical data for ME-344 in HER2 negative breast cancer patients is attached hereto as Exhibit 99.2, each of which is hereby incorporated herein by reference.
Item 8.01. Financial Statements and Exhibits.
MEI Pharma, Inc. ExhibitEX-99.1 2 d596104dex991.htm EXHIBIT 99.1 Exhibit 99.1 Exhibit 99.1 MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 90% Objective Response Rate Observed in Patients with Indolent B-Cell Malignancies SAN DIEGO,…To view the full exhibit click
About MEI Pharma, Inc. (NASDAQ:MEIP)
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.